Recent Articles By The Author
Gilead Buying Vertex Among Bold Biotech Stock Predictions for 2015
The 2015 biotech stock predictions of TheStreet contributor David Sobek.
2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests
Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.
Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
The diversification away from Xtandi has only just begun.
Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths
Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.
Acceleron Hit Over Competitive Concerns, but Investors Overlook Rest of Pipeline
An Acceleron update in December could reignite investor interest in the stock.
Safety Worries Over Celgene's Experimental Crohn's Drug Overblown
The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
Tetraphase Oral Antibiotic Data Look Good
Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.
Previewing Tetraphase Oral Antibiotic Study Results
Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.